Lasmiditan binds with high affinity to the 5-HT1F receptor. Lasmiditan presumably exerts its therapeutic effects in the treatment of migraine through agonist effects at the 5-HT1F receptor; however, the precise mechanism is unknown.
Lasmiditan is indicated for the acute treatment of migraine with or without aura in adults.
Limitations of Use:
REYVOW is not indicated for the preventive treatment of migraine.
Therapeutic Category : Antimigraine
CAS Number : 439239-90-4
Molecular Formula : C19H18F3N3O2
Molecular Weight : 872.8 g/mol
Mesh Size : As per Customer Requirement
Jolly Healthcare Development Status : Wishlist